182 related articles for article (PubMed ID: 29239000)
1. Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.
Ismail M; Lee VH; Chow CR; Rubino CM
J Clin Pharmacol; 2018 Apr; 58(4):541-548. PubMed ID: 29239000
[TBL] [Abstract][Full Text] [Related]
2. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Greenblatt DJ; Patel M; Harmatz JS; Nicholson WT; Rubino CM; Chow CR
J Clin Pharmacol; 2018 Apr; 58(4):533-540. PubMed ID: 29194698
[TBL] [Abstract][Full Text] [Related]
3. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
4. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Xu R; Ge W; Jiang Q
Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492
[TBL] [Abstract][Full Text] [Related]
5. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.
Moore KT; Vaidyanathan S; Natarajan J; Ariyawansa J; Haskell L; Turner KC
J Clin Pharmacol; 2014 Dec; 54(12):1407-20. PubMed ID: 24964176
[TBL] [Abstract][Full Text] [Related]
6. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Cheong EJY; Teo DWX; Chua DXY; Chan ECY
Drug Metab Dispos; 2019 Nov; 47(11):1291-1306. PubMed ID: 31506301
[TBL] [Abstract][Full Text] [Related]
7. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
8. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
Wen HN; He QF; Xiang XQ; Jiao Z; Yu JG
Thromb Res; 2022 Oct; 218():24-34. PubMed ID: 35985100
[TBL] [Abstract][Full Text] [Related]
9. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.
Brings A; Lehmann ML; Foerster KI; Burhenne J; Weiss J; Haefeli WE; Czock D
Br J Clin Pharmacol; 2019 Jul; 85(7):1528-1537. PubMed ID: 30912163
[TBL] [Abstract][Full Text] [Related]
10. Coming full circle: The potential utility of real-world evidence to discern predictions from a physiologically based pharmacokinetic model.
Grillo JA; McNair D; Zhao P
Biopharm Drug Dispos; 2023 Aug; 44(4):344-347. PubMed ID: 37345420
[TBL] [Abstract][Full Text] [Related]
11. Persistent Rivaroxaban Effect Due to Impaired Renal Clearance and Medication Effects.
Milito C; McRae H; Victor A; Refaai MA; Schmidt AE
Lab Med; 2020 Mar; 51(2):211-216. PubMed ID: 31340380
[TBL] [Abstract][Full Text] [Related]
12. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.
Grillo JA; Zhao P; Bullock J; Booth BP; Lu M; Robie-Suh K; Berglund EG; Pang KS; Rahman A; Zhang L; Lesko LJ; Huang SM
Biopharm Drug Dispos; 2012 Mar; 33(2):99-110. PubMed ID: 22270945
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.
Li Z; Yang S; Hua Z; Lu Y; Li X
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3351-3362. PubMed ID: 37950768
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
[TBL] [Abstract][Full Text] [Related]
15. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
[TBL] [Abstract][Full Text] [Related]
16. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Becka M; Mueck W; Halabi A; Maatouk H; Klause N; Lufft V; Wand DD; Philipp T; Bruck H
Br J Clin Pharmacol; 2010 Nov; 70(5):703-12. PubMed ID: 21039764
[TBL] [Abstract][Full Text] [Related]
17. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
18. Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.
Sia JEV; Lai X; Wu X; Zhang F; Li H; Cui C; Liu D
Eur J Pharm Sci; 2023 Mar; 182():106376. PubMed ID: 36626944
[TBL] [Abstract][Full Text] [Related]
19. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
20. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
